The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova A.S.

Nadareyshvili G.G.

Pirogov Russian National Research Medical University, Moscow, Russia

Gulieva M.Sh.

Pirogov Russian National Research Medical University, Moscow, Russia

Antithrombotic treatment as primary and secondary prevention of stroke

Authors:

Chukanova E.I., Chukanova A.S., Nadareyshvili G.G., Gulieva M.Sh.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10): 85‑88

DOI: 10.17116/jnevro201611610185-88

Read: 1175 times

Download PDF (RU)
Contact the author
Table of contents

ANTITHROMBOTIC TREATMENT AS PRIMARY AND SECONDARY PREVENTION OF STROKE
ANTITHROMBOTIC TREATMENT AS PRIMARY AND SECONDARY PREVENTION OF STROKE

To cite this article:

Chukanova EI, Chukanova AS, Nadareyshvili GG, Gulieva MSh. Antithrombotic treatment as primary and secondary prevention of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10):85‑88. (In Russ.)
https://doi.org/10.17116/jnevro201611610185-88

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Adju­vant pharmacological modu­lation with Cyto­flavin in reha­bilitation at stages 2—3 in patients with acute cere­bral insu­fficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
10-year dyna­mics of cardiovascular status in combination with coro­nary angiography data in men of working age in the Arctic region of resi­dence and the south of the Tyumen region. Russian Journal of Preventive Medi­cine. 2025;(4):30-38
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Triglycerides-Glucose Index as an inte­gral biomarker of insu­lin resi­stance and cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2025;(5):124-129
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Correlation between endo­thelial dysfunction and sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2025;(3):13-18
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
Abstract:

The use of antithrombotic drugs (ATD) is necessary in the treatment and prevention of thrombosis. The correction of risk factors of ischemic stroke (IS) and transitory ischemic attacks (TIA) is important as well. The drugs inhibiting the activation and aggregation of thrombocytes allow to decrease the number of myocardial infarctions by 35%, stroke by 25% and mortality from cardiovascular causes by 15%. Currently, the clinical efficacy of acetylsalicylic acid (ASA), thienopyridines (ticlopidine, clopidogrel), dipyridamole or the combination of dipyridamole and ASA as well as glycoprotein antagonists IIb-IIIa for intravenous introduction have been confirmed. A review of experimental and clinical studies confirming the efficacy of dipyridamole in the treatment of acute stage of stroke and primary and secondary prevention of II is presented.

Keywords:

cerebrovascular disease
ischemic stroke
endothelial dysfunction
antitrombotic druds
dipyridamol

Authors:

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova A.S.

Nadareyshvili G.G.

Pirogov Russian National Research Medical University, Moscow, Russia

Gulieva M.Sh.

Pirogov Russian National Research Medical University, Moscow, Russia

Close metadata

References:

  1. Gusev EI, Skvorcova VI, Stahovskaja LV. Jepidemiologija insul'ta v Rossii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova (Prilozhenie «Insul't»). 2003;8:4-9. (In Russ.).
  2. Chukanova EI. Discirkuljatornaja jencefalopatija (Klinika, diagnostika, lechenie): Dis. ... d-ra med. nauk. 2004. (In Russ.).
  3. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA. 2002;3:99(18):11946-11950. doi: 10.1073/pnas.182296499
  4. Hinderliter AL, Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2003;5, 6:506-513. doi: 10.1007/s11883-003-0042-x 
  5. Yung Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42:11:3323-3328. doi: 10.1161/strokeaha.110.608257 
  6. Chukanova EI, Chukanova AS, Mamaeva HI. Rezul'taty issledovanija jeffektivnosti i bezopasnosti primenenija meksidola u pacientov s hronicheskoj ishemiej mozga. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;2:71-74. (In Russ.).
  7. Luscher TF, Noll G. The endothelium as a regulator of vascular tone and growth. The endothelium in cardiovascular disease: pathophysiology, clinical presentation, and pharmacotherapy. Berlin. 1995. doi: 10.1007/978-3-642-79803-0_1 
  8. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. doi: 10.1136/bmj.324.7329.71 
  9. Popova LV, Bokarev IN, Arkad'eva GV, Radzevich AJe, Mazurov AV. Protivotrombocitarnaja terapija v klinicheskoj praktike. Metodicheskie rekomendacii. 2007. (In Russ.).
  10. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;1146:683-698. doi: 10.1378/chest.114.5_supplement.683s
  11. Fitzgerald GA. Dipyridamole. N Engl J Med. 1987;316:1247-1257.
  12. Balacumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varathalingam R, Dhanaraj SA. Classical and pleotropic action of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacological Research. 2014;87:144-150. doi: 10.1016/j.phrs.2014.05.008 
  13. Heistad DD, Marcus ML, Gourley JK, Busija DW. Effect of adenosine and dipyridamole on cerebral blood flow. Am J Physiol. 1981;240:775-780.
  14. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541. doi: 10.1126/science.1068711 
  15. Vorob'eva OV. Antitrombocitarnye i nejroprotektivnye jeffekty dipiridamola (ot klinicheskih modelej k praktike). Trudnyj pacient. 2010;3-7. (In Russ.).
  16. Iuliano L, Pedersen JZ, Rotilio G. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med. 1995;18:239-247. doi: 10.1016/0891-5849(94)e0123-z 
  17. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186.
  18. Kusmic C, Petersen E, Picano E. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J Cardiovasc Pharmacol. 2000;36. doi: 10.1097/00005344-200008000-00001
  19. Hasday JD, Sitrin RG. Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: a possible mechanism of antithrombotic action. Blood. 1987;69:660-667.
  20. Aktas B, Utz A, Hoening-Liedl P, Walter U, Deiger J. Dipyridamole enhances N/c GMF-mediated vasodilator — stimulated phosphoprotein phosphorylation and signaling in human platelets: in vivro and in vivo/ex vivo studies. Stroke. 2003;34:764-769. doi: 10.1161/01.str.0000056527.34434.59 
  21. Lip G, Kamath S, Hart R. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ. 2002;325:1161-1163. doi: 10.1136/bmj.325.7373.1161
  22. Diener HC, Cunha L, Fordes C, Sivenius J, Smets P, Loventhal A. European Stroke Prevention Study 2 Dipiridamol and Acetylsalicyllic Acid in secondary prevention of stroke. J Neurologocal Sci. 1996;143:1-13. doi: 10.1016/s0022-510x(96)00308-5 
  23. Ringleb PA, Bousser MG, Ford G et al. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack. 2008. (www.eso-stroke.org).
  24. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367(9523):1665-1673. doi: 10.1016/s0140-6736(06)68734-5 
  25. Dickerson L, Carek P, Quattlebaum R. Prevention of recurrent ischemic stroke. Am Fam Physician. 2007;76(3):382-388.
  26. Lee M, Saver JL, Hong SK, Rao NM, Wu YL, Ovbiagele B. Risk-benefit profile of long-term dual-versus singleantiplatelet therapy among patients with ischemic stroke: a systematic review and metaanalysis. Ann Intern Med. 2013;159(7):463-4670. doi: 10.7326/0003-4819-159-7-201310010-00006 
  27. Malloy R, Kanaan A, Silva M, Donovan J. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Clin Ther. 2013;35(10):1490-1500. doi: 10.1016/j.clinthera.2013.09.004 
  28. Sharma A, Khanna D, Balakumar P. Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats. Int J Cardiol. 2014;172(2):530-532. doi: 10.1016/j.ijcard.2014.01.053 
  29. Adams RJ, Albers G, Alberts MJ et al. American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39(5):1647-1652. doi: 10.1161/strokeaha.107.189063 
  30. d͗ Esterre CD, Lee T-Y. Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits. Annals of the York Academy of Sciences. 2010;71-75. doi: 10.1111/j.1749-6632.2010.05801.x 
  31. Tanashjan MM, Domashenko MA. Primenenie kurantila pri hronicheskom cerebrovaskuljarnom zabolevanii. Atmosfera. Nervnye bolezni. 2005;3:8-11. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.